Good's Syndrome Complicated with COVID-19 and Recurrent Pulmonary Infections: A Case Report.

IF 1.5 4区 医学 Q4 ALLERGY
Wenjuan Xia, Mengqi Wu, Fang He
{"title":"Good's Syndrome Complicated with COVID-19 and Recurrent Pulmonary Infections: A Case Report.","authors":"Wenjuan Xia, Mengqi Wu, Fang He","doi":"10.18502/ijaai.v25i2.20805","DOIUrl":null,"url":null,"abstract":"<p><p>Good's syndrome (GS), a rare immunodeficiency disorder characterized by thymoma and hypogammaglobulinemia, presents diagnostic and therapeutic challenges due to recurrent infections. We report a 53-year-old male farmer with GS complicated by recurrent pulmonary infections and COVID-19. Initial management focused on antiviral/anti-infective therapy and corticosteroids, but persistent hypogammaglobulinemia, B-cell depletion, and thymoma history were overlooked. Diagnosis was confirmed upon integrating the thymoma history, immunological profiling, and bronchial alveolar lavage-next generation sequencing, revealing Pneumocystis jirovecii and Herpes Simplex Virus-1 coinfections. Treatment with intravenous immunoglobulin loading dose (2 g/kg), pathogen-targeted therapy (voriconazole, cotrimoxazole), and tapered corticosteroids achieved clinical remission, with immunoglobulin G (IgG) elevating to 6.35 g/L. This case underscores the necessity of a \"four-dimensional early warning system\" integrating thymoma history, immune, imaging, and pathogen for timely GS diagnosis. Multidisciplinary collaboration and personalized regimens combining immunoglobulin replacement, precision anti-infectives, and immunomodulation are pivotal for optimizing outcomes in GS patients with complex infections.</p>","PeriodicalId":14560,"journal":{"name":"Iranian journal of allergy, asthma, and immunology","volume":"25 2","pages":"269-278"},"PeriodicalIF":1.5000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian journal of allergy, asthma, and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18502/ijaai.v25i2.20805","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Good's syndrome (GS), a rare immunodeficiency disorder characterized by thymoma and hypogammaglobulinemia, presents diagnostic and therapeutic challenges due to recurrent infections. We report a 53-year-old male farmer with GS complicated by recurrent pulmonary infections and COVID-19. Initial management focused on antiviral/anti-infective therapy and corticosteroids, but persistent hypogammaglobulinemia, B-cell depletion, and thymoma history were overlooked. Diagnosis was confirmed upon integrating the thymoma history, immunological profiling, and bronchial alveolar lavage-next generation sequencing, revealing Pneumocystis jirovecii and Herpes Simplex Virus-1 coinfections. Treatment with intravenous immunoglobulin loading dose (2 g/kg), pathogen-targeted therapy (voriconazole, cotrimoxazole), and tapered corticosteroids achieved clinical remission, with immunoglobulin G (IgG) elevating to 6.35 g/L. This case underscores the necessity of a "four-dimensional early warning system" integrating thymoma history, immune, imaging, and pathogen for timely GS diagnosis. Multidisciplinary collaboration and personalized regimens combining immunoglobulin replacement, precision anti-infectives, and immunomodulation are pivotal for optimizing outcomes in GS patients with complex infections.

Good’s综合征合并新冠肺炎并发复发性肺部感染1例
古德氏综合征(GS)是一种罕见的以胸腺瘤和低γ -球蛋白血症为特征的免疫缺陷疾病,由于复发性感染,给诊断和治疗带来了挑战。我们报告一例53岁男性农民GS合并复发性肺部感染和COVID-19。最初的治疗重点是抗病毒/抗感染治疗和皮质类固醇,但忽视了持续性低γ -球蛋白血症、b细胞耗损和胸腺瘤病史。结合胸腺瘤病史、免疫学谱和支气管肺泡灌洗-下一代测序,确诊为乙氏肺囊虫和单纯疱疹病毒-1合并感染。静脉注射免疫球蛋白负荷剂量(2 g/kg)、病原体靶向治疗(伏立康唑、复方新诺明)和锥形皮质类固醇治疗达到临床缓解,免疫球蛋白g (IgG)升高至6.35 g/L。该病例强调了“四维早期预警系统”的必要性,该系统将胸腺瘤病史、免疫、影像学和病原体结合起来,以便及时诊断GS。多学科合作和结合免疫球蛋白替代、精确抗感染和免疫调节的个性化方案是优化复杂感染GS患者预后的关键。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
6.70%
发文量
64
审稿时长
>12 weeks
期刊介绍: The Iranian Journal of Allergy, Asthma and Immunology (IJAAI), an international peer-reviewed scientific and research journal, seeks to publish original papers, selected review articles, case-based reviews, and other articles of special interest related to the fields of asthma, allergy and immunology. The journal is an official publication of the Iranian Society of Asthma and Allergy (ISAA), which is supported by the Immunology, Asthma and Allergy Research Institute (IAARI) and published by Tehran University of Medical Sciences (TUMS). The journal seeks to provide its readers with the highest quality materials published through a process of careful peer reviews and editorial comments. All papers are published in English.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书